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In vivo, eukaryotic cells are subjected simultaneously to a broad array of signals ranging from mitogens and inflammatory inputs to
environmental stresses and developmental cues. The combinatorial nature of cellular signaling necessitates that a cell integrate its signal
transduction pathways so as to implement rapidly and efficiently an appropriate suite of responses. Emerging evidence indicates that, over the
course of evolution, cells have developed multiprotein signaling complexes, or “signalosomes” that mediate the coordinate regulation of different
signaling pathways. Such molecular signal integration contrasts with the classical notion of signaling complexes assembled by scaffold proteins—
entities that function to segregate specific pathways from one another. This review will focus on two signal integrating multiprotein complexes that
involve Raf family kinases: the MLK3-B-Raf–Raf-1 complex and the Raf-1–Mst-2 complex.
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The first mammalian MAPK was identified as an insulin-
stimulated protein Ser/Thr kinase regulated by concomitant Tyr
and Thr phosphorylation, that could itself phosphorylate and
activate Rsk — at the time, only the second multistep protein
Ser/Thr kinase cascade (after the PKA cascade) to be described
for mammalian cells [1–3]. Molecular cloning of the insulin-
stimulated enzyme, ERK, revealed its striking structural
homology to yeast enzymes (Fus3p, Kss1p) [4]. Over the
ensuing 20 years there has been an explosion of understanding
of mammalian MAPK pathways, culminating in the identifica-
tion of at least six mammalian MAPK groups (and an overall
total of as many as 13 individual MAPK genes—many with
multiple hnRNA splicing isoforms) [5,6].
Virtually all MAPKs are regulated by concomitant Tyr and
Ser/Thr phosphorylation. This regulation occurs as a three tiered
mechanism wherein MAPKs are activated by MAPK kinases
(MKKs or MEKs) which, in turn, are regulated by Ser/Thr⁎ Tel.: +1 617 636 5190; fax: +1 617 636 5204.
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Mammalian MAP3K regulation – indeed all MAP3K regula-
tion – is complex and has been remarkably recalcitrant to
biochemical or genetic analysis. There are, however, some
common themes in MAP3K regulation. Thus, many of these
enzymes are regulated in part by binding to small GTPases of
the Ras superfamily. The Raf kinases are examples of such
regulation. Superimposed on this regulation is regulation by
phosphorylation (either autocatalyzed, or catalyzed by kinases
that, in most cases have yet to be identified), oligomerization,
binding of adapter proteins such as 14-3-3 (see the article by
Tzivion in this issue), and regulation by scaffold proteins [5,6].
The identification of signaling pathway scaffolding proteins
provided critical insight into a key question concerning MAPK
regulation: How is a given MAPK with multiple functions in
vivo segregated so as to enable it to be selectively recruited in
response to a single stimulus, without engaging extraneous
pathways that can also be regulated by this MAPK, but which
are not needed for an appropriate response to the indicated
stimulus? Scaffold proteins sequester multiple signaling com-
ponents into complexes arrayed to respond to one, or a small set
of distinct stimuli.
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identified. Thus, the MAP3K Ste11p can function in both the
mating pheromone response pathway and in the high osmolarity
response pathway. The scaffold protein Ste5p tethers Ste11p to
the MKK Ste7p and the MAPKs Fus3p and Kss1p to form a
MAPK module responsive to mating pheromone [7,8]. By
contrast, the MKK Pbs2p performs a secondary scaffold
function tethering Ste11p to itself and to the MAPK Hog1p as
part of the osmoadaptation pathway [9]. Scaffold proteins for
both the ERK (MP1, MORG) and JNK (the JIPs) pathways
have been identified, and are discussed elsewhere in this issue.
The notion of pathway segregation raises a complementary
question. How does a cell respond to several simultaneous,
possibly divergent signals in a coordinated manner? Inasmuch
as cells rarely exist in a situation in which, at a given time, they
experience only single discrete stimuli, it is evident that a cell
must integrate at multiple levels the response mechanisms for
simultaneous, divergent signals. The ability of key signaling
components to interact and form multiprotein complexes
permits coordinate regulation of these process in space and
time.
This review will highlight two such metazoan cell MAPK
signal integration mechanisms: the mixed lineage kinase-3
(MLK3)-B-Raf-Raf-1 complex and the Raf-1–Mst-2 complex.
These examples are by far not a complete survey of such signal
integrating mechanisms, but are meant instead to illustrate the
emerging notion of pathway signal integration by MAP3Ks.
2. MLK3, B-Raf, Raf-1 and the integration of JNK and
ERK signaling
A principal function of MAPK pathways is to regulate the
activity of transcription factors [5,6,10,11]. Frequently, these
transcription factors are oligomeric and under the parallel
control of multiple MAPKs. The activator protein-1 (AP-1)
transcription factor is an illustrative example which highlights
the importance of coordinating the activation of inputs that feed
into transcription factor activation.
c-Jun is a component of AP-1, a heterodimer that consists of
c-Jun plus either other members of the Jun family, c-Fos or ATF2
[11]. Each AP-1 component is under complex regulation, both at
the transcriptional, and posttranslational level—regulation
mediated in large part by MAPKs [5,6,10,11]. Thus, the JNKs
were identified as the major MAPKs responsible for phosphor-
ylation of the c-Jun amino terminus at Ser63 and 73—a process
that has been linked to enhanced transcriptional activity
[5,6,12–16]. Although the JNKs are strongly recruited by
environmental stresses and proinflammatory cytokines, there
are several instances in which the JNKs are activated by
mitogens [14–16]. Indeed, the ability of JNKs to bind and
phosphorylate c-Jun has been linked to the promotion of cell
survival and proliferation [17]. While the JNKs can regulate the
Jun family and ATF2, the ERKs and JNKs can promote c-fos
transcription through the phosphorylation and activation of Elk1
[5,6,18–21]. c-Fos itself is activated in part by phosphorylation
catalyzed by both ERK and its substrate kinase Rsk [22]. This
complex regulation requires the coordinate activation of JNKand ERK. The ability of MLK3 to function both as a direct
activator of JNK-specific MKKs and as an adapter in the
activation of the Rafs, and through them, the ERKs illustrates
one mechanism by which ERK and JNK can be coordinately
regulated. However, to understand the relationship between
MLK3, B-Raf and Raf-1, it is necessary to review briefly the
interregulatory relationship between B-Raf and Raf-1.
Mammalian raf-1 was cloned in 1983 as the transforming
oncogene of the murine retrovirus 3611-MSVand, in parallel as
the transforming oncogene of the avian leukemia virus MH2.
A-Raf was isolated from a murine cDNA library in 1986. Two
years later, B-raf was cloned as the transforming oncogene of
human Ewing sarcoma. Genetic studies placed Raf-1 down-
stream of Ras; and some biochemical studies indicated that raf-
1 transformation coincided with enhanced ERK activation
[23–28]. But it was not until 1992 that MEK was identified as a
substrate for Raf-1 [29–31]. A- and B-Raf can also readily
phosphorylate MEK [28,32,33].
Activation of Raf proteins commences with the binding of
GTP-Ras to the amino terminal Ras binding domain (RBD) and
cysteine-rich domain (CRD) [28,34–38]. This binding is
followed by a series of important phosphorylation events that
lead eventually to activation. For Raf-1 in resting cells, S259 is
phosphorylated by Akt [39]. This residue is dephosphorylated
by phosphatase-2A—coincident with Ras binding [39,40].
14-3-3 proteins can bind to phosphorylated S259, S233 and
S621 [41,42]. Dephosphorylation of Raf-1 S259 leads to 14-3-3
dissociation from this site; however, 14-3-3 can remain bound
to the other sites. Indeed, phosphorylation of S621 is critical for
activation; and there is some thought that a cycling of
differential Raf-1 phosphorylation and 14-3-3 binding may
contribute to activation (see article by Tzivion in this issue)
[28,42]. Raf-1 also requires Ras-dependent phosphorylation at
several other sites including Y341 (possibly catalyzed by Src)
and S338 (possibly catalyzed by p21-activated kinases—PAKs)
[43,44]. Phosphorylation or Raf-1 at S471 is also a critical step
that promotes MEK binding [45]. Of note, Raf-1 also requires
for activation the Ras-dependent phosphorylation of T491 and
S494, two residues in the kinase domain activation loop. The
kinase(s) responsible for this phosphorylation is/are unknown
[46].
In addition, the Rafs are assembled into a competent
signaling complex via the binding of two molecular chaper-
onins: Hsp90 and Cdc37, both of which are required for Raf-1
activation [47]. Of note, MLK3 also requires Hsp90 and Cdc37
for signaling [48]; and these chaperonins may participate in
coupling MLK3 to the Rafs (see below).
Finally, several scaffold and adapter proteins have been
linked to Raf-1 activation. Often these function in a cell and/
or stimulus-dependent fashion. Kinase suppressor of Ras-1
(Ksr1), a Raf-like pseudokinase binds both MEK1 and Raf-1
and serves to ‘‘present’’ MEK1 to Raf-1 [49–51]. Scaffolds
of the connector-enhancer of Ksr (CNK) link different
mitogens to Raf-1 activation and increase the efficiency of
Raf-1 signaling in situ (for example, CNK2 is required for
NGF activation of ERK while CNK1 is required for insulin
activation of ERK) [52–55]. Interestingly, in transfection/
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and the closely related MLK2. This interaction may promote
the coupling of Rho family GTPases to JNK [56]. However,
inasmuch as (i) CNKs are also linked to Raf and ERK
activation [52–55] and (ii) MLK3 has been linked to the
activation of B-Raf and ERK (see below), it will be important
to determine if CNK1 or CNK2 is relevant to the maintenance
of the B-Raf-MLK3 signaling complex and to MLK3's
contribution to ERK activation (see below).
The leucine-rich repeat protein suppressor of Ras mutations-
8 (Sur8) forms a ternary complex with Raf-1 and Ras that is
important to mitogen (EGF) activation of ERK [57]. By
contrast, MAPK organizer 1 (MORG1) and MEK partner-1
(MP1) organize a complex of Raf-1, MEK and ERK for
activation by LPA, PMA and serum, but not EGF [58,59].
Similarly, the evolutionarily conserved protein prohibitin
interacts directly with Raf-1 and is required for coupling Raf-
1 to Ras in response to EGF [60]. The dynamic interrelation-
ships among these different scaffold proteins, as well as any
functions for these scaffolds in the regulation of other Raf
family members or MLK3 remain to be established.
B-Raf regulation is less well understood than that of Raf-1,
although it is likely somewhat simpler, and involves amino
acids conserved with those of Raf-1. S365 and S729 correspond
to Raf-1 S259 and S621 and likely form core 14-3-3 binding
sites [28,43,61]. S446, which corresponds to Raf-1 S338,
appears to be constitutively phosphorylated while D449, which
corresponds to Raf-1 Y341, bears a negative charge which
mimics the charge imparted by phosphorylation of Raf-1 Y341
[28,43,61]. Accordingly, while B-Raf S446 and D449 are
critical to maintaining B-Raf in an active state, neither residue
contributes to signal-dependent B-Raf regulation. finally, B-Raf
T599 and S602 correspond to Raf-1 T491 and S494.
Phosphorylation of B-Raf at T599 and S602 is similarly Ras-
dependent and is absolutely required for activation [46,62].
Although all Raf isoforms can phosphorylate and activate
MEKs-1 and -2, gene knockout studies indicate more
complicated in situ and in vivo roles for the different Raf
isoforms. Thus, neither B-Raf nor Raf-1 can compensate for
loss of the other in vivo. Disruption of raf-1 leads to increased
sensitivity to apoptogenic stresses, but does not impair signaling
by mitogens to ERK. By contrast, deletion of B-raf abolishes
ERK activation [63–65]. Additional gene disruption studies
did, however, suggest a mutual interregulatory relationship
between the B-Raf and Raf-1 [66,67]. The link between MEK
regulation and the in vivo role of A-Raf is less well understood.
A-raf is located on the X chromosome, and disruption of A-raf
is conditionally lethal, depending upon the genetic background.
Thus, in C57 BL/6 mice, disruption of A-raf is embryonic
lethal, while disruption in 129/OLA mice results in mice that are
viable and fertile. The reasons for this discrepancy are unclear;
however, both knockout mice manifest neurological defects,
without an apparent systemic impairment of ERK activation
[68].
Over 30 mutations in B-raf have been associated with human
cancers—principally malignant melanoma [28,61,69]. Simi-
larly, six mutations in B-raf have been linked to cardio-facio-cutaneous syndrome (CFC), a rare, sporadic developmental
disorder that presents with characteristic craniofacial, cardiac
and ectodermal defects, along with developmental delay [70].
The most common B-raf mutation linked to melanoma is
V600E, which results in a constitutively active enzyme that
potently activates MEK1 in situ[28,61,69]. Most, but not all of
the mutations in B-raf linked to CFC are also constitutively
active (many as active as V600E) [70], and it is unclear why the
constitutively active CFC mutations are not transforming
in vivo—although this may be due to a paradoxical ability of
activated B-Raf, in the absence of collaborative transforming
lesions in other genes, to trigger a cell senescence-like cell cycle
arrest [71].
The ability of B-Raf to regulate Raf-1 was first examined in
detail coincident with an analysis of mutations in B-Raf
associated with human cancers. Of particular interest, a
systematic biochemical analysis of the transforming alleles of
B-raf, along with those linked to CFC, revealed that not all of
these mutations possessed highly elevated activity in vitro
[70,72,73]. Specifically, at least three B-rafalleles linked to
cancer, G466E, G466Vand G596Rmanifest impaired activity in
vitro, but can still potently activate MEK in intact cells,
constitutively and independently of Ras [72,73]. This disparity
is due to the ability of the mutants to trans activate Raf-1 in situ.
Interestingly, the G596V mutation in CFC, like the G596R
mutation in melanoma, manifests impaired activity in vitro [63];
however, its in situ activity is unknown. Consistent with the idea
of B-Raf trans activation of Raf-1, RNAi silencing of raf-1
abolishes the ability of the melanoma-associated, impaired
activity B-Raf mutants to trigger ERK activity in situ. Wild type
B-Raf, in a Ras-dependent manner, can also trans activate Raf-1
in situ. However, Raf-1 cannot trans activate B-Raf [72,73].
The ability of B-Raf to activate Raf-1 requires the formation
of a heteromer of B-Raf and Raf-1 (Fig. 1). The oncogenic,
impaired activity mutants of B-Raf can bind Raf-1 in situ
constitutively, in a Ras-independent manner—likely accounting
for its dysfunctional activation in cancer. By contrast, the binding
of wild type B-Raf and Raf-1 is Ras-dependent [73,74].
Consistent with the importance of the activation loop segment
and 14-3-3-binding phosphoacceptor sites (T491/S494 and S621,
respectively) of Raf-1, mutagenesis of any of these sites to non
phosphorylatable residues ablates activation of Raf-1 by B-Raf;
and 14-3-3 proteins appear to be particularly important for B-
Raf-Raf-1 heteromerization [73]. It is unclear, however, whether
or not B-Raf actually phosphorylates Raf-1 at these sites. A role
in B-Raf/Raf-1 heteromerization for the scaffold proteins linked
to Raf-1 regulation also remains to be established.
That MLK3 was critical to in ERK signaling was somewhat
unexpected given the nature of previous findings concerning
MLK3 function. MLK3 was cloned in 1994 as part of a screen
for protein kinases expressed in B cells [75,76]. Independently,
MLK3 was cloned in a yeast two hybrid screen as an interactor
with the Ste20 homologue hematopoietic progenitor kinase-1
(HPK1) [76,77]. Biochemical and overexpression studies
indicated that MLK3 was a JNK- and, to a lesser extent, p38-
specific MAP3K (phosphorylating and activating the JNK-
specific MAPK-kinases [MKKs] MKK4 and MKK7 as well as
Fig. 1. Hypothetical model for the regulation of proliferative signaling by
multiprotein complexes as mediated by MAP3Ks. Receptor Tyr kinases (RTK in
the figure) activate Ras and promote Raf activation with the context of a
complex that includes B-Raf, Raf-1 and MLK3, as well as 14-3-3s and phos-
phatase-2A (PP2A in the figure). This complex enables coordinate activation of
JNK and ERK, inhibition of Mst2 and consequent promotion of cell
proliferation and survival. The diagram has been somewhat simplified so as
to highlight topics discussed in this review. Details are in the text.
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dependent production of the putative second messenger
ceramide [77–79]. MLK3 is activated by mitogens and is also
clearly recruited by the Rho family GTPases Rac1 and,
especially, Cdc42, which can trigger MLK3 activation by
fostering phosphorylation of MLK3 at the activation loop sites
T277 and T281 [80,81]. However, neither Rac nor Cdc42 has a
significant, direct role in ERK activation [5,6,76] (Fig. 1).
Pharmacologic studies that exploited a specific ATP competi-
tive MLK inhibitor supported the idea that MLK3 was a JNK-
specific MAP3K [82,83].
Although transfection studies indicated initially that MLK3
could not activate coexpressed ERK in situ [77,78], there were
some studies that suggested a link between MLK3 and ERK
activation. Thus, upon stable overexpression, MLK3 can
transform NIH3T3 cells in a manner that is partially reversed
by the synthetic MEK1 inhibitor PD98059 or upon coexpres-
sion of a dominant inhibitory MEK construct [84]. Moreover,
ectopically overexpressed MLK3 is a potent activator of MEK1
in situ and in vitro [85]. The inability of MLK3 to activate ERK
in spite of strong MEK1 activation has been attributed to the
JNK-dependent induction of an as yet unidentified ERK
inhibitor [85]. It is unclear if this inhibitor is produced in
response to endogenous MLK3 recruitment of JNK.
mlk3 is easily silenced by RNAi and this approach has
provided clues as to the cellular functions of MLK3. RNAi
silencing of mlk3 blocks JNK activation by both mitogens andproinflammatory cytokines. Cytokine activation of p38 is also
blocked upon silencing of mlk3 [86]. Of note, however,
silencing mlk3 by RNAi blunted mitogen and cytokine
activation of ERK in multiple, diverse cell types [86]—this,
in spite of the observation noted above [85] that ectopic
expression of MLK3 did not trigger ERK activation. The effects
of this RNAi could be reversed upon ectopic expression of
recombinant MLK3 from a heterologous species [86].
AlthoughMLK3 can activateMEK1 [85,86], the requirement
for MLK3 for mitogen activation of ERK extends upstream of
MEK (Fig. 1). Thus, mitogen activation of B-Raf—including
phosphorylation at the critical activation loop residues (T599,
S602) is completely ablated upon silencing of mlk3 [86,87].
Interestingly, silencing of mlk3 has no apparent effect on the
phosphorylation of Raf-1 at T491 and S494 [86]. The
significance of this finding is somewhat unclear, however,
insofar as the activation of Raf-1 is complex. Accordingly, we do
not know if MLK3 is required for other required regulatory
steps, aside from T491/S494 phosphorylation, that are involved
in Raf-1 activation. It is worth noting that the observation that
silencing ofmlk3 is absolutely required for B-Raf activation, but
is without effect on Raf-1 phosphorylation at T491/S494
contrasts with the observations that B-Raf is necessary for
Raf-1 activation. That said, although T491A/S494A Raf-1 is no
longer activated by B-Raf [73], this Raf-1 construct is refractory
to all stimuli [46]; and therefore the molecular mechanism by
which B-Raf contributes to Raf-1 activation is still somewhat
unclear.
MLK3 does not phosphorylate B-Raf at T599/S602; and the
ability of MLK3 to affect ERK activation is apparently
noncatalytic inasmuch as ectopic expression of a kinase-
inactive mutant of MLK3 can rescue the defect in mitogen
activation of B-Raf and ERK incurred by silencing endogenous
mlk3 [86,87]. MLK3 interacts in situ with both B-Raf and Raf-1
and is necessary for maintenance of the B-Raf/Raf-1 hetero-
oligomer necessary for Raf activation [86,87] (Fig. 1). Thus,
silencing of mlk3 abolishes the interaction between B-Raf and
Raf-1—a process required for B-Raf activation [73,87].
The exact molecular composition of the complex containing
MLK3, B-Raf and Raf-1 remains unclear. As mentioned above,
B-Raf, Raf-1 and MLK3 associate with an overlapping suite of
chaperonins and scaffold proteins, chiefly CNK1, Hsp90 and
Cdc37 [47,48,52–56]. There is evidence that both MLK3 and
Raf-1 require Hsp90/Cdc37 for activity [47,48]; and CNK1 is
also important to both ERK and JNK activation [52–56].
Accordingly, it will be important to determine if these proteins
contribute to coupling MLK3 to the Rafs.
The requirement for MLK3 for JNK as well as B-Raf and
ERK activation has dramatic consequences for cell prolifera-
tion. It is well established that recruitment of the ERK pathway
is key to the ability of mitogens to trigger cell proliferation.
Thus, prolonged, intense ERK activation is required for mitogen
induction of cyclin D1 and for cell cycle entry [88–90].
Likewise JNK phosphorylation of c-Jun is critical not only to
inhibition of apoptosis but to cell proliferation as well [17,91–
93]. Coincident with inhibition of ERK activation, silencing of
mlk3 strikingly blocks serum-stimulated cell proliferation and
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toma protein (Rb) at S807/S811 [86]. Phosphorylation of Rb at
S807 and S811 occurs at the G1/S phase of the cell cycle and is
necessary for subsequent induction of cyclin-D and cell cycle
progression [94]. Thus, MLK3 is required for G1/S cell cycle
progression. Consistent with a role, in G1/S cell cycle
progression, for MLK3 regulation of ERK, pharmacologic
inhibition of ERK, but not JNK also strikingly impairs cell
proliferation [86].
Likewise, the proliferation of ras-, but not raf-1-transformed
NIH3T3 cells is blocked by mlk3 RNAi [86], an observation
that fits well with the idea of a role for MLK3 downstream of
Ras and upstream of B-Raf. Moreover, the proliferation of
human colon adenocarcinoma cells bearing activating muta-
tions in Ki-ras, but not those bearing activating (V600E)
mutations in B-raf also requires MLK3 [86]. Similarly, the
proliferation of human neurofibromatosis-1 schwannoma cells
with loss of function mutations in nf1, which encodes the Ras
GTPase activating protein neurofibromin [95], is also blunted
nearly completely upon silencing of mlk3 [86]. Interestingly, as
is discussed further below, similar results were obtained when
mlk3 was silenced in neurofibromatosis-2 schwannoma cells
bearing loss of function mutations in nf2 [87], which encodes
the ezrin-radixin-moesin protein merlin [96].
The noncatalytic role of MLK3 in the regulation of B-Raf,
ERK and cell proliferation (Fig. 1) sheds additional light on
the results of experiments using CEP1347, a pharmacologic
agent that inhibits all MLK isoforms, but which is particularly
potent as an inhibitor of MLK3 [82]. CEP1347 is an ATP
competitor and completely blunts the catalytic activity of
MLK3 in vitro and in situ [82]. Accordingly, CEP1347 would
not be expected to affect situations in which the MLK3
polypeptide was required independently of its catalytic
function. CEP1347 potently ablates Rho GTPase recruitment
of JNK in situ [82]. However, the proliferation of asynchro-
nous, Ha-ras-transformed fibroblasts is unaffected by
CEP1347 employed at concentrations that completely inhibit
MLK3 [83]. By contrast, CEP-1104, a second broad spectrum,
ATP-competitive MLK inhibitor blocks cell cycle exit at G2/
M, when administered to synchronized cells [97]. The
significance of this result with regard to the noncatalytic role
of MLK3 in ERK regulation [86,87] is unclear inasmuch as
silencing of mlk3 and the consequent inhibition of ERK
activation affect cell cycle entry at G1/S in serum-starved (G0)
stimulated with serum to reenter the cell cycle [86]. It is quite
reasonable to posit that MLK3 has a catalytic role in G2/M
that (i) would be sensitive to pharmacologic inhibition and (ii)
might be obscured by the noncatalytic G1/S MLK3 function—
given the fact that for serum-starved cells reentering the cell
cycle, G1/S progression is a prerequisite for G2/M. Interest-
ingly, in support of a G2M role for MLK3, gene disruption
studies indicate that MKK7, a key MLK3 substrate, is required
for G2/M transition [93]. Thus MLK3-catalyzed activation of
MKK7 may be important to G2/M, while the noncatalytic
regulation of B-Raf by MLK3 is required for G1/S.
These findings run counter to results recently reported for
mice in which mlk3 has been disrupted. These mice are viableand fertile, but show only a partial loss of TNF activation of
JNK, with no other notable impairment of MAPK (ERK or p38)
signaling [98]. These mice also show a reduced epidermal
thickness along the dorsal midline [98]. This observation is
interesting given that it resembles the dorsal closure defects
observed for Drosophila in which slipper, the sole Drosophila
MLK isoform, has been disrupted [76] (see article by Rana in
this issue).
Disruption of mlk3 may, however, alter MAPK regulation of
adipogenic potential. Thus, during adipogenesis (stimulated by
treatment with insulin/isobutyl-methylxanthine followed by
troglitizone), mlk3−/− mouse embryo fibroblasts (MEFs)
manifest a slight decrease in JNK activation, a slight increase
in p38 activation and no change in ERK activation. Fat
deposition in the cells is potentiated in the mlk3−/− cells as
evidenced by increased oil red-O staining [98]. Of note, this is
consistent with the observation that JNK can phosphorylate and
inhibit the activity of the adipogenic transcription factor
peroxisome proliferator activator receptor (PPAR)-γ [99].
However, it has not been shown if, during adipogenesis of
MEFs, PPARγ phosphorylation is affected by disruption of
mlk3.
It is unclear why, in contrast to cultured cells, cells from
mlk3−/− mice do not show significant impairment of MAPK
regulation. One plausible reason is that MLKs closely related to
MLK3 (especially the structurally similar MLK2) can be
recruited to compensate in vivo for MLK3, thus enabling the
development of an apparently normal mouse. Cultured cells,
while expressing MLK2, would not be expected to possess such
compensatory mechanisms when subjected to short term mlk3
RNAi—especially given the observation that silencing of mlk3,
while arresting cells at G1/S, is not cytotoxic [86].
3. Signal integration by merlin, MLK3, the Rafs and Mst2
The existence of a signaling complex between MLK3, B-Raf
and Raf-1 was surprising, but it provides a common node
through which JNK and ERK can be coordinately activated
(Fig. 1). Recent findings suggest that the Rafs (Raf-1 in this
case) interact with and inhibit additional signaling components
that regulate apoptosis.
A series of elegant genetic studies of Drosophila has
dissected a highly conserved proapoptotic and antiproliferative
signaling pathway that is positively regulated by the merlin
tumor suppressor protein. A similar mechanism likely exists in
human cells, where a principal component, the protein kinase
mammalian Sterile-20-like kinase-2 (Mst2) is negatively
regulated by Raf-1.
The relationship between cell proliferation and apoptosis is
complex; and there is evidence that many proliferative
pathways can also trigger apoptosis—presumably as part of a
“failsafe” mechanism to prevent excessive proliferation.
Accordingly, concerted or unregulated cell proliferation, as
occurs in cancer, typically requires the suppression of apoptosis
pathways. Likewise, appropriate programmed cell death
requires the coordinate inhibition of proliferation and the
promotion of apoptosis.
Fig. 2. Antiproliferative signals or apoptogens, possibly through merlin, or other
mechanisms lead to disruption of the B-Raf/Raf-1/MLK3 complex, release and
activation of Mst2 (via dimerization and autophosphorylation). Cell cycle arrest
and apoptosis are the consequences. The Drosophila Hpo pathway is shown for
comparison to the mammalian Mst2 pathway. In this instance the link between
Drosophila merlin and Rafs is not established. The diagram has been somewhat
simplified so as to highlight topics discussed in this review. Details are in the
text.
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components are often tightly conserved evolutionarily with
those of humans, have provided much needed insight into the
interregulatory relationships between cell proliferation and
apoptosis. A particularly powerful system for such analysis is
the development of the Drosophila compound eye. In this
system, cell proliferation and apoptosis occur in a stereotyped
manner, proceeding along a morphogenetic furrow that moves
across the eye imaginal disc from posterior to anterior. Anterior
to the furrow cells divide asynchronously. Within the furrow,
cells synchronize in G1. Posterior to the furrow, cells either
undergo one round of synchronous division or exit the cell cycle
and differentiate into ommatidia. Superfluous cells remaining
after differentiation are eliminated by a wave of apoptosis. Gene
products regulating this pathway have been identified, all of
which are highly conserved with human proteins implicated in
cancer.
hippo (hpo) was identified as a gene the loss of function of
which results in elevated expression of cyclin E (an enhancer of
proliferation) and Drosophila inhibitor of apoptosis-1 (diap1)—
an apoptosis inhibitor. Loss of hpo triggers an overgrowth
phenotype in the developing compound eye—an overgrowth
that arises due to the excessive proliferation, and impaired
apoptosis of interommatidial cells [100,101]. Thus, Hpo
promotes cell cycle exit and apoptosis and contributes to
normal developmental tissue homeostasis in vivo. Of particular
note, hpo is the Drosophila orthologue of the mammalian Ser/
Thr kinase mammalian sterile-20-like kinase-2 (Mst2); and
introduction of human mst2 rescues hpo loss of function
[100,101].
The eye phenotype arising from loss of hpo is remarkably
similar to that reported for loss of several other highly
conserved genes: the adapter protein salvador (sav), the protein
Ser/Thr kinase warts (wts), mob as tumor suppressor (mats—
another adapter protein) and the transcription factor yorkie (yki)
[100–108]. Genetic and biochemical studies suggest that Hpo
interacts directly with Sav to facilitate Hpo-catalyzed phos-
phorylation and activation of Wts, which exists as a complex
with Mats. Wts–Mats then phosphorylates and inactivates Yki
which is necessary for normal expression of diap1 and cyclin E
[100–108] (Fig. 2).
Thus, targeted eye-specific deletion of hpo or wts leads to
increased transcription of diap and cyclin E, and similar
deletion of mats also triggers increased cell proliferation and
defective apoptosis [100–106]. Conversely, overexpression of
yki results in increased cell proliferation and defective apoptosis
[107]. Coordinate overexpression of hpo or wts results in 100%
lethality at an early pupal stage. This is completely reversed
upon overexpression of yki [107]. Taken together, these findings
demonstrate the antagonistic relationship between hpo/wts and
yki [100–108].
Conservation of this pathway is remarkable (Fig. 2). Large
tumor suppressors-1 and -2 (Lats1/2) are mammalian ortholo-
gues of Wts [105,108,109]. Mst2 can phosphorylate and
activate both Lats1 and Lats2. Mass spectrometric analysis
has identified S909 in the kinase activation loop, and T1079 in a
conserved hydrophobic motif as the sites on Lats1 phosphory-lated by Mst2. In addition, Mst2 interacts directly with hWW45,
a putative orthologue of Sav [102,108]. Of note, introduction of
a human Mats orthologue (Mats1) or yes-associated protein
(YAP), a human orthologue of yki can rescue loss of the cognate
Drosophila proteins [106,107].
In mammals, Raf-1 likely functions as a negative regulator of
Mst2. Disruption of raf-1 leads to widespread apoptosis and
embryonic lethality. However, ERK regulation, which is
mediated primarily by B-Raf, is largely unaffected [63–65].
raf1−/− fibroblasts are strongly sensitive to apoptogenic stress
stimuli such as serum withdrawal, chemical toxins or activation
of Fas [63,64]. Interestingly, a mutant form of Raf-1 that cannot
undergo activation (YY340-341FF) completely rescues the
proapoptotic phenotype of raf-1 disruption [63,64], suggesting
that the kinase activity of Raf-1 is not required for its
antiapoptotic function.
Mst2 was identified by mass spectrometry as a Raf-1
interactor [109]. Mst2 can interact in situ with either wild type
(wt) or kinase inactive (YY340-341FF or K375M) Raf-1. This
interaction is inhibited by some stimuli (staurosporine or FasL,
but not serum withdrawal) that promote apoptosis. The
dissociation of the Mst2–Raf-1 complex is associated with
Mst2 activation and occurs independently of any effect on Akt,
suggesting that, as in Drosophila, Mst2 functions to promote
death signaling, rather than inhibit survival signaling. Mst2 is
apparently required for the enhanced apoptosis observed in
raf-1−/− cells inasmuch as silencing of mst2 by RNAi reverses
the enhanced Fas or staurosporine-induced cell death that
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compelling as they argue against a nonspecific Raf-1–Mst2
interaction. However, whereas a role for Fas in apoptosis is of
profound physiologic significance, the relevance of staurospor-
ine to physiologic or developmental apoptosis is less evident. It
will be important to determine if a broad array of physiologi-
cally relevant apoptogens functions in part via disruption of
Raf-1–Mst2; and, conversely, if cytoprotective mechanisms
promote the Raf-1–Mst2 interaction.
Raf-1 interferes with Mst2 activation at several levels. Mst2
is activated by homodimerization followed by transphosphor-
ylation of T180 in the kinase activation loop [110]. Both wt and
kinase-dead Raf-1, when introduced into raf-1−/− cells, can
lead to the disassembly of Mst2 homodimers constitutively
present in the raf-1−/− cells, and prevent phosphorylation of
Mst2 at T180 [109]. As a consequence, Mst2 activity is ablated.
It is thought that the Raf-1-mediated deactivation of Mst2
involves phosphatase-2A, which associates with Raf-1 [40]
(Fig. 1, compare with Fig. 2). Thus, Raf-1 immunoprecipitates
can promote dephosphorylation of recombinant Mst2 in vitro in
a manner reversed by the phosphatase 2A inhibitor okadaic
acid. Thus, Raf-1 restricts Mst2 homodimerization and actively
fosters Mst2 dephosphorylation [109].
Whether or not Hpo is negatively regulated by Drosophila
Raf (dRaf) is unclear. dRaf is structurally more similar to
mammalian B-Raf, which does not interact with Mst2 [109]. We
also do not know if the integrity of the B-Raf–Raf-1 complex –
notably that regulated by MLK3 – is necessary for Mst2
binding.
However, recent findings indicate that the Hpo pathway is
regulated by the Drosophila orthologues of the neurofibroma-
tosis-2 (NF2) gene product merlin and expanded [111] (Fig. 2).
If these mechanisms are conserved in mammals, there could be
links between mammalian merlin and Raf-1/Mst2 via MLK3.
Like their human orthologues, Drosophila merlin(mer) and
expanded (ex) encode protein 4.1-ezrin-radixin-moesin (FERM)
domain proteins [96,111]. Mammalian merlin is a tumor
suppressor protein that interacts with numerous cytosolic and
transmembrane proteins including p21-activated kinase-1 (PAK1),
CD44, hepatocyte growth factor-regulated tyrosine kinase sub-
strate (HRS), PI-3-kinase enhancer-L isoform (PIKE-L), Na+/H+
exchanger type 3 regulatory cofactor (NHE-RF) and (see below)
MLK3 [96]. These interactions generally serve to suppress cell
proliferation and promote apoptosis.
Like Hpo, Wts, Mts and Yki, Mer and Ex are required for cell
proliferation cell cycle arrest and apoptosis in developing
imaginal discs [111]. Thus, eye-specific deletion/inactivation of
mer and/or ex results in dysfunctionally excessive expression of
cyclin E and diap. Genetic epistasis studies of Drosophila place
both Mer and Ex upstream of Hpo (Fig. 2). Thus, eye-targeted
transgenic overexpression of ex leads to a striking increase in
eye cell apoptosis, reduced proliferation and retarded eye
development manifested as a loss of interommatidial cells, a
disruption of ommatidial morphology and reduced eye size
[111]. Loss of hpo function reverses the effect of ectopic Ex.
Mer and Ex also function to trigger enhanced phosphorylation of
Wts and Yki—downstream targets of Hpo. Likewise, hyper-activation of Hpo (by overexpression) rescues the increase in
cyclin E and diap observed upon loss of ex expression. Thus,
Mer and Ex function to promote activation of Hpo, and its
downstream effectors Wts and Yki [111].
How might this relate to conserved elements in mammalian
cells? As noted above, the mammalian Hpo orthologue Mst2
activates the mammalian Wts orthologue Lats1; and Mst2 itself
is negatively regulated by Raf-1 [108,109]. Optimal activation
of Raf-1 requires that it be in a complex with B-Raf [72,73], and
the integrity of this complex requires MLK3 [86,87] (Fig. 1).
We have observed that mammalian merlin, expressed from an
inducible vector, can trigger the disruption of the B-Raf/Raf-1
complex coincident with the inhibition of ERK activation [87]
(Fig. 2). Moreover, mammalian merlin and MLK3 coimmuno-
precipitate, and ectopic expression of merlin can disrupt the
interaction of MLK3 and B-Raf as well as the interaction
between MLK3 and Raf-1 [87] (Fig. 2).
Might merlin also trigger the disruption of the Raf-1/Mst2
interaction? We do not yet know. As was mentioned above, the
kinase activity of Raf-1 is not required for its interaction with
and inhibition of Mst2 [109]; and merlin appears to disrupt the
formation of multiprotein complexes that promote B-Raf and
Raf-1 activation; however, this effect appears to be constitutive
whereas stresses and apoptogens can reverse Raf-1 inhibition of
Mst2 [87,109]. However, this does not rule out the possibility
that (i) MLK3 may not only foster activation of the Rafs, but
may promote Raf functions that are independent of kinase
activity (e.g., binding and inhibiting Mst2), or (ii) that merlin, in
a manner not regulated by extracellular stresses or apoptogens,
by suppressing MLK3's effects on the Rafs, may also foster
Mst2 release from Raf-1 and consequent activation of the Mst2
pathway.
4. Conclusions and perspectives
The organization of Raf kinases into signaling complexes
with other proximal kinases, including, but not limited to
MAP3Ks such as MLK3, allows for a strong degree of signal
integration that permits the cell to process and respond to
concomitant diverse stimuli. The existence of these complexes
raises important questions for further research.
Chief among these questions is how is the organization of
Raf-containing complexes regulated? As noted above, the trans
activation of Raf-1 by B-Raf – in nontransformed cells –
appears to be dependent upon Ras (by contrast, activating
mutations in B-Raf bypass this regulation). However, the
precise molecular mechanism that underlies this regulation is
still unclear. MLK3 associates with the B-Raf/Raf-1 complex
apparently constitutively, and the steps that lead to Raf
activation in response to engagement of Ras remain incomple-
tely elucidated Similarly, FasL and staurosporine activate Mst2
promoting its dissociation from Raf-1. However, the mechan-
ism that links either of these stimuli to Mst2 activation remain to
be determined. Of note, the role of merlin in positively
regulating Mst2 in response to extracellular stimuli is still
nebulous. We do not observe any stimulus-dependent binding/
dissociation of merlin from MLK3. Thus, merlin (which is
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sequestering MLK3 constitutively from the Rafs, may function
merely to influence the intensity and duration of subsequent Raf
activation. Merlin may play a similar role in Mst2 regulation.
We also do not know how mechanisms that promote signal
integration versus mechanisms that promote signal segregation
(e.g., true scaffold proteins) differentially influence cellular
responses at a given time. This may in part be a matter of the
repertoire of binding partners for individual signaling compo-
nents. Thus, for example, MLK3 may function as both a signal
integrator and direct MAP3K in response to mitogens—in part
through its interaction with the Rafs. By contrast, MLK3, when
functioning in proinflammatory signaling, may be sequestered
from the Rafs via interactions with more specific scaffold
proteins. Alternatively, different multiprotein complexes may
form and dissociate with the time course of sustained agonist
stimulation.
Clearly, the complex interactions among proximal protein
kinases and adapters upstream of MAPKs represent a challenge
for molecular biology and for the development of new thera-
peutic strategies.
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